Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02913742
Other study ID # Pro00074452
Secondary ID
Status Withdrawn
Phase N/A
First received September 22, 2016
Last updated April 27, 2017
Start date March 2017
Est. completion date December 2019

Study information

Verified date August 2016
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Mesial temporal lobe epilepsy (MTLE) is the most common cause of medication-resistant epilepsy in adults, and MRI-guided laser interstitial thermal therapy is a new approach to its surgical management; however, while LITT demonstrates fewer complications than traditional surgical techniques, it generates lower rates of seizure freedom. During traditional temporal lobectomy for MTLE, neurophysiologic intraoperative monitoring (NIOM) can be used to better identify epileptogenic tissue and guide resection. Our study proposes to investigate the utility of NIOM during LITT for MTLE. Subjects will be drawn from refractory mesial temporal lobe epilepsy patients determined to be candidates for LITT. During their LITT surgery, in addition to the placement of the stereotactic LITT probe, subjects will receive a second smaller stereotactic electrode for intraoperative monitoring of epileptic discharges before and after surgery. After surgery, at regularly scheduled follow-ups, patients will receive the Quality of Life in Epilepsy questionnaire (QOLIE-31-P), in addition to standard post-operative care. Endpoints will be surgical complications, fractional decrement in epileptiform discharges from pre- to post-ablation recordings, and surgical outcome at 6 months and one year. Analysis of severe complications will be expressed as a simple complication rate, for overall complications, severe complications, and hemorrhagic complications in specific. The relationship between fractional discharge decrement and outcome will be assessed by regression analysis. Risks of the study will stem from the placement of the stereotactic electrode for intraoperative monitoring, which represents a small incremental risk beyond typical LITT for MTLE.


Description:

Mesial temporal lobe epilepsy (MTLE) is the most common cause of medication-resistant epilepsy in adults. The standard treatment for refractory MTLE is surgical resection by craniotomy. Stereotactic laser interstitial thermal therapy (LITT) is a new surgical technique being used to treat MTLE. Under MRI-guidance, a laser probe is inserted into the seizure focus and heat is used to destroy the tissue. Compared to temporal lobectomy, LITT results in shorter hospital stays, low complication rates, and possibly less cognitive decline; however, seizure freedom rates are potentially lower.

During temporal lobectomy, neurophysiologic intraoperative monitoring (NIOM) can be used to better identify epileptogenic tissue and guide resection. This tool has been unavailable during LITT procedures. Recently, the investigators demonstrated in two cases that NIOM with a depth electrode is technically feasible during LITT and can identify epileptiform activity intra-operatively.

This is a prospective trial of NIOM during LITT for mesial temporal lobe epilepsy. The investigators will assess the safety of performing NIOM during LITT and whether data from NIOM (frequency and characteristics of epileptiform discharges recorded before and after ablation) are associated with seizure outcomes. If there is an association, NIOM could be used for prognostication and could potentially even be used to guide surgery.

Hypotheses:

1. NIOM performed by MRI-guided stereotactic depth electrode placed in the parahippocampal gyrus adjacent to the LITT catheter is safe, as compared to institutional LITT controls without NIOM and published LITT complication rates.

2. Greater magnitude fractional decrements in discharge frequency from pre-ablation to post-ablation recordings will be significantly associated with better seizure outcomes, as measured by International League Against Epilepsy (ILAE) surgical outcome scores.

Objectives:

The primary project goals are to assess if NIOM by parahippocampal depth electrode is safe during LITT of MTLE and to assess if the fractional decrement of interictal discharges (ID) on NIOM can be significantly correlated with outcome. The study will be powered to address these questions a priori. Post hoc analyses consisting of a multivariate analysis of other patient demographic data, NIOM findings, operative parameters, quality of life scores, and neuropsychiatric outcomes will also be assessed.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2019
Est. primary completion date November 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria are as follows

1. Age = 18

2. The patient must suffer from drug resistant mesial temporal lobe epilepsy as determined by a consensus of providers at weekly epilepsy surgery conferences held by the Duke Epilepsy Center

3. The patient must be a candidate for LITT for MTLE as determined by a consensus of providers at weekly epilepsy surgery conferences held by the Duke Epilepsy Center

Exclusion criteria are as follows

1. Age = 18

2. Lack of consensus on localization of MTLE

3. Multifocal epilepsy

4. History of prior epilepsy surgery

5. Lack of consensus on candidacy for LITT

6. Pregnancy

7. Patient without capacity to provide legal consent

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
monitoring by depth electrode
During laser interstitial thermal ablation (LITT) for mesial temporal lobe epilepsy, the study patients will receive invasive neurophysiologic intraoperative monitoring. In addition to the typical placement of LITT stereotactic laser ablation probe via occipital burr hole, the study patients will receive an 8-contact depth recording electrode placed through an adjacent burr hole. The recording electrode will be placed into the parahippocampal gyrus in parallel to the LITT device. The patient will be monitored for epileptic discharges for 10 minutes before and 10 minutes after the ablation process to record the change in discharges during the surgery. The monitoring will not be used to guide surgery. The probe will be removed with the LITT device at the end of the procedure.

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Luedke MW, Pietak MR, Serafini S, Haglund MM, Sinha SR. Intraoperative ECoG During MRI-Guided Laser-Interstitial Thermal Therapy for Intractable Epilepsy. J Clin Neurophysiol. 2016 Aug;33(4):e28-30. doi: 10.1097/WNP.0000000000000299. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary fractional decrement in interictal epileptiform discharges (ID) from pre- to post-ablation Analysis of NIOM ID recordings will focus on fractional decrement of discharge counts from pre- to post-operative recordings. Fractional decrement was chosen, as opposed to absolute discharge counts, which are expected to vary widely among patients. Fractional discharge decrement will be assessed for its association with surgical outcome. 30 day post-operative course
Primary Surgical complications associated with intraoperative monitoring electrodes and recording Analysis of safety will occur in an ongoing fashion, and at completion of the trial. Major complications will be reviewed immediately per institutional review board (IRB) approved protocols, and will trigger a project safety evaluation. Moderate and minor complications will be recorded, with results reviewed quarterly, to assess project safety. Final safety results will be compared to registry data of institutional MTLE LITT procedures and to published LITT results for MTLE. Perioperative through 30 days post-operation
Secondary Epilepsy surgery outcome Outcome will be measured by the ILAE surgical outcome 6-point scale. Fractional ID decrement will be analyzed for their association with surgical outcomes. Perioperative through 30 days post-operation
See also
  Status Clinical Trial Phase
Completed NCT00001672 - Language Localization Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Epilepsy N/A
Active, not recruiting NCT04897776 - Stimulation of the Thalamus for Arousal Restoral in Temporal Lobe Epilepsy N/A
Recruiting NCT05947656 - Evaluation of the NaviFUS System in Drug Resistant Epilepsy N/A
Not yet recruiting NCT06036732 - A New Approach in Intensive Care Unit Consciousness Assessment: FIVE Score
Recruiting NCT04164056 - Hippocampal and Thalamic DBS for Bilateral Temporal Lobe Epilepsy Phase 4
Completed NCT03265925 - Brain Network Activation Analysis in Epilepsy
Enrolling by invitation NCT02151175 - Low-intensity Focused Ultrasound Pulsation (LIFUP) for Treatment of Temporal Lobe Epilepsy N/A
Recruiting NCT03478852 - Investigating Epilepsy: Screening and Evaluation
Recruiting NCT01273129 - Surgery as a Treatment for Medically Intractable Epilepsy
Not yet recruiting NCT06057233 - Innovative MRI to Localize the Epileptic Zone
Recruiting NCT04649008 - Localizing Epileptic Networks Using MRI and iEEG Early Phase 1
Completed NCT00931619 - GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression
Recruiting NCT04717388 - Pathophysiology, Psycho-emotional and Cognitive Functioning Associated With Tinnitus N/A
Completed NCT00706160 - Language Mapping in Patients With Epilepsy
Recruiting NCT05339438 - Pre-operative Mapping of the Anterior Temporal Lobe Using Functional MRI Innovative Techniques in in Drug-resistant Epileptic Patients N/A
Not yet recruiting NCT04871555 - Structural Cartography of the Insula in Temporal Epilepsy Patients
Completed NCT04169581 - A Deep Learning Framework for Pediatric TLE Detection Using 18F-FDG-PET Imaging
Completed NCT00040326 - Early Surgical Intervention to Treat Epilepsy Phase 3
Not yet recruiting NCT06422923 - Effect of NRTX-1001, a Cellular Therapy Product, for the Treatment of Refractory Bilateral TLE Phase 1
Recruiting NCT03871842 - Effects of tDCS on Depressive Symptoms of Participants With Temporal Lobe Epilepsy N/A